Hospira, a Pfizer (NYSE: PFE) company and a leading provider of
infusion technologies, today announced the launch of the LifeCare
PCA® 7.0 Infusion System.
As the first patient-controlled analgesia (PCA) infusion pump to
offer electronic medical record (EMR) integration (also known as
I.V.-EMR interoperability), LifeCare PCA 7.0 is a next-generation
infusion system. It enables device auto-programming and streamlines
documentation of infusion data to help improve the safety and
efficiency of pain management medication administration.
It's the first and only PCA pump with integrated bar code
identification of prefilled and pharmacy-filled drug vials,
substantially eliminating the potential for drug and concentration
errors at the bedside. Medication errors affect 1.5 million people
and cost $21 billion annually, and the EMR integration and bar-code
technology help give health care providers confidence that the
right drug is being administered to the patient at the right dose
and in the right concentration.1,2
The LifeCare PCA 7.0 system has been granted clearance by the
U.S. Food and Drug Administration (FDA) with enhanced cybersecurity
protections. It features new security options, which include:
- Hospital-configured device passwords
and enhanced protection of customer network security settings,
helping to prevent unauthorized access.
- Automatic detection and closure of
unused network communications ports, limiting remote access points
to the device and network.
- Updated communications engine
technology, including removal of telnet service, thereby
eliminating remote administrator, or root access, to the pump.
Additionally, through Hospira MedNet v6.1 next-generation safety
software, LifeCare PCA 7.0 includes new alarm-forwarding
functionality.
In support of Hospira's global device strategy to deliver new
technologies, this marks the fourth Hospira infusion system product
launch in the last 24 months. The new LifeCare PCA 7.0 device
debuted this week at the American Association of Critical-Care
Nurses (AACN) National Teaching Institute & Critical Care
Exposition in New Orleans.
"Hospira is proud to deliver the first PCA smart pump that can
integrate directly with the EMR," said Julie Sawyer Montgomery,
president, U.S. Infusion Systems, Hospira. "With the new
integration capabilities and enhanced cybersecurity features, the
clearance of LifeCare PCA 7.0 ushers in a new phase in IV-EMR
connectivity and pain management therapy. It also underscores
Hospira's leadership in delivering technology to meet the evolving
needs of health care providers in medication error prevention and
clinician efficiency."
For Pennsylvania-based Lancaster General Health -- a
pioneer in infusion pump integration --integrating the
LifeCare PCA 7.0 to the hospital EMR is the next evolution in their
medication safety platform.
"Because the LifeCare PCA 7.0 system allows integration to the
order in the EMR, it will help us minimize risk associated with a
nurse or clinician manually programming an infusion pump," said
Tina Suess, MHA, BSN, RN-BC, CPHIMS, manager, Medication Safety
Integration, Lancaster General Health.
Michael Ripchinski, MD, MBA, Chief Quality and Medical
Information Officer, Lancaster General Health, also remarked, "It
also enables improvement in the safety of administering high-risk
narcotics. Improvements in the safety and efficacy of pain
management have become a critical issue for institutions across the
country. Integrating the LifeCare PCA 7.0 to the EMR increases
transparency for clinicians, especially when changing patients
from intravenous to oral medications."
The new LifeCare PCA 7.0 device is available for customers to
order. Launching the first hospital PCA device in the industry more
than 30 years ago, Hospira revolutionized pain management therapy
as a PCA technology innovator.3 According to the KLAS report,
"Smart Pump/EMR Integration," the company has implemented
integrated EMR technology at more hospitals than all other infusion
pump providers combined, and with more major EMR platforms than any
other company.4
About Hospira
Hospira, a Pfizer company, is a leading provider of infusion
technologies. The company's focused infusion systems portfolio
features I.V. solutions, proven, innovative smart pumps, and pain
management and safety software technology designed to help meet
clinical, safety and workflow goals. Learn more at
www.hospira.com.
Pfizer Inc.; Working together for a healthier world®
At Pfizer, we apply science and our global resources to bring
therapies to people that extend and significantly improve their
lives. We strive to set the standard for quality, safety and value
in the discovery, development and manufacture of health care
products. Our global portfolio includes medicines and vaccines, as
well as many of the world's best-known consumer health care
products. Every day, Pfizer colleagues work across developed and
emerging markets to advance wellness, prevention, treatments and
cures that challenge the most feared diseases of our time.
Consistent with our responsibility as one of the world's premier
innovative biopharmaceutical companies, we collaborate with health
care providers, governments and local communities to support and
expand access to reliable, affordable health care around the world.
For more than 150 years, Pfizer has worked to make a difference for
all who rely on us. To learn more, please visit us
at www.pfizer.com. In addition, to learn more, follow us on
Twitter @Pfizer and @Pfizer_News, LinkedIn, YouTube and like us on
Facebook at Facebook.com/Pfizer.
DISCLOSURE NOTICE: The information contained in this release is
as of May 19, 2016. Pfizer assumes no obligation to update
forward-looking statements contained in this release as the result
of new information or future events or developments.
This release contains forward-looking information regarding
Hospira’s LifeCare PCA 7.0 Infusion System, including its potential
benefits, that involves substantial risks and uncertainties that
could cause actual results to differ materially from those
expressed or implied by such statements. Risks and uncertainties
include, among other things, uncertainties regarding the commercial
impact of LifeCare PCA 7.0 Infusion System; uncertainties
regarding regulatory approvals in any other jurisdictions to market
the LifeCare PCA 7.0 Infusion System may be received; and
competitive developments.
A further description of risks and uncertainties can be found in
Pfizer’s Annual Report on Form 10-K for the fiscal year ended
December 31, 2015 and in its subsequent reports on Form 10-Q,
including in the sections thereof captioned “Risk Factors” and
“Forward-Looking Information and Factors That May Affect Future
Results,” as well as in its subsequent reports on Form 8-K, all of
which are filed with the U.S. Securities and Exchange Commission
and available at www.sec.gov and www.pfizer.com.
1 Institute of Medicine of the National Academies. Preventing
Medication Errors. Washington, DC: The National Academies Press;
2007. Available at www.nap.edu
2 National Priorities Partnership and National Quality Forum.
Preventing Medication Errors: A $21 Billion Opportunity.
Washington, DC; December 2010. Available at www.psnet.ahrq.gov
3 Frazier, S. R. Patient Controlled Analgesia: More than
twenty-five years in the making" Where are we now? ASPMN 19th
National Conference, September 15, 2009
4 Hess P. Smart Pump/EMR Integration -- What Are My Best
Options? May 2015 Performance Report, pages 2,8. Available at
www.klasresearch.com
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160519005720/en/
PfizerMedia:Rachel Hooper,
916-708-1868Rachel.Hooper@pfizer.comorInvestor:Bryan Dunn,
212-733-8917Bryan.Dunn@pfizer.com
Pfizer (NYSE:PFE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pfizer (NYSE:PFE)
Historical Stock Chart
From Apr 2023 to Apr 2024